Dasatinib Plus Quercetin for Accelerated Aging in Mental Disorders

Summary

This pilot open-label study examines the effects of a combination of dasatinib plus quercetin - two drugs that have known senolytics properties - on physiological aging in older individuals with depression or schizophrenia.

Eligibility

Inclusion Criteria:

1. Either major depression, which is treatment-resistant (currently depressed despite at least 2 adequate trials of antidepressants in this or the previous episode), or schizophrenia/schizoaffective disorder.
2. Age 50+ (60+ for depression).
3. Three conditions associated with aging (e.g., hypertension/diabetes/metabolic syndrome, cardiac disease, lung disease other than asthma, cancer with adult-onset, arthritis, and inflammatory diseases typically seen in aging).
4. No history of dementia by patient report.
5. Already taking an adequate dose of medication for schizophrenia/schizoaffective disorder or depression.

Exclusion Criteria:

1. Contraindications for dasatinib or quercetin
2. Active SI such that participant could not be safely managed in an outpatient clinical trial.
3. Taking medications that are strong CPY3A4 inhibitors or strong inducers, or that induce senescence (e.g., alkylating agents, anthracyclines, platins/other chemotherapy), or everolimus and topotecan (which have interactions with quercetin).
4. All medications and medical conditions will be reviewed by physician study investigators to determine whether the medication or condition, in the opinion of the investigators, makes the participant inappropriate for the study. Examples of such potential excluding conditions: Active inflammatory, infectious, or malignant disease; sensory deficits that would interfere with assessments; recent heart attack or stroke; severe bleeding disorder; uncontrolled hypertension or diabetes mellitus; active liver disease or cirrhosis; current use of systemic steroids, quinolone antibiotics, hydroxychloroquine or chloroquine.

Conditions4

Interventions2

Locations1 site

Find trials near these locations

Related trials

• Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) — Canadian Cancer Trials Group
• Dasatinib Combined With Quercetin to Reverse Chemo Resistance in Triple Negative Breast Cancer — Fudan University
• Dose Individualization of Antineoplastic Drugs and Anti-Infective Drug in Children With Hematoplastic Disease — Wei Zhao
• Evaluation of DASATINIB Monotherapy Efficacy in Acute Myeloid Leukemia Patients Refractory to VENETOCLAX-AZACITIDINE — Institut Paoli-Calmettes
• HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies — Princess Maxima Center for Pediatric Oncology
• Newly-diagnosed Pediatric T-cell ALL Protocol — Institute of Hematology & Blood Diseases Hospital, China
• Pilot Trial for Treatment of Recurrent Glioblastoma — AHS Cancer Control Alberta
• Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer — Oslo University Hospital

Browse More Trials